Adam R. Winstock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Adam R. Winstock has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Toby Lea
Centre for Social Research in Health, UNSW Australia, Sydney, New South Wales, Australia
6 shared publications - Janie Sheridan
School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
2 shared publications Alison Ritter
National Drug and Alcohol Research Centre (NDARC), University of New South Wales, Australia
1 shared publicationAnnie Madden
Australian Injecting and Illicit Drug Users' League (AIVL), Canberra, ACT, Australia
1 shared publicationGilbert Whitton
1 shared publicationMaria Nittis
1 shared publication
Latest Publications
- 1 January 2009
- Published by Elsevier in International Journal of Drug Policy
- Vol. 20 (1) , 85-89
Opioid dependent patients’ experiences of and attitudes towards having their injecting sites examined
- 1 January 2009
- Published by Elsevier in International Journal of Drug Policy
- Vol. 20 (1) , 85-89
Opioid dependent patients’ experiences of and attitudes towards having their injecting sites examined
- 1 December 2008
- Published by Elsevier in International Journal of Drug Policy
- Vol. 19 (6) , 450-458
Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia
- 1 December 2008
- Published by Elsevier in International Journal of Drug Policy
- Vol. 19 (6) , 450-458
Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia
- 1 November 2008
- Published by Wiley in Drug and Alcohol Review
- Vol. 27 (6) , 671-678
Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment
Introduction and Aims. A consumer satisfaction survey was conducted among clients receiving methadone or buprenorphine treatment for opioid dependence. The survey aimed to assess client perceptions across a number of treatment domains, including the clinic environment, service provision, clinical relationships, medication and treatment outcomes. Design and Methods. Participants were 432 clients receiving treatment at nine public clinics in New South Wales, Australia. An interviewer‐administered questionnaire was utilised, designed by the researchers. Participation was voluntary and anonymous. All participants received $10 remuneration. Results. Seventy‐eight per cent of participants were on methadone treatment. Overall satisfaction with treatment was high (mean: 3.8; very satisfied = 5). Participants were mainly satisfied with service provided by the clinic, although had concerns over the inflexibility associated with the clinic atmosphere, frequency of clinic attendance, dosing hours and lack of takeaway doses. While relationships with prescribers and case managers were rated positively, 16% and 21% of participants wanted to see their prescriber and case manager more often, respectively; 53% reported that they did not have input into their care plan. Regarding the helpfulness of case managers in assisting clients with problems experienced in identified domains of case management (e.g. drug use, physical and mental health, psychosocial supports), the mean rating was 5.2 (excellent = 10). Discussion and Conclusions. While participants reported being mainly satisfied with their treatment, results must be viewed within the context of what a consumer reasonably expects to receive from a service. The concept of ‘expectation’ and ‘relative experience’ is crucial in measuring consumer satisfaction among pharmacotherapy consumers.
- 1 November 2008
- Published by Wiley in Drug and Alcohol Review
- Vol. 27 (6) , 671-678
Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment
Introduction and Aims. A consumer satisfaction survey was conducted among clients receiving methadone or buprenorphine treatment for opioid dependence. The survey aimed to assess client perceptions across a number of treatment domains, including the clinic environment, service provision, clinical relationships, medication and treatment outcomes. Design and Methods. Participants were 432 clients receiving treatment at nine public clinics in New South Wales, Australia. An interviewer‐administered questionnaire was utilised, designed by the researchers. Participation was voluntary and anonymous. All participants received $10 remuneration. Results. Seventy‐eight per cent of participants were on methadone treatment. Overall satisfaction with treatment was high (mean: 3.8; very satisfied = 5). Participants were mainly satisfied with service provided by the clinic, although had concerns over the inflexibility associated with the clinic atmosphere, frequency of clinic attendance, dosing hours and lack of takeaway doses. While relationships with prescribers and case managers were rated positively, 16% and 21% of participants wanted to see their prescriber and case manager more often, respectively; 53% reported that they did not have input into their care plan. Regarding the helpfulness of case managers in assisting clients with problems experienced in identified domains of case management (e.g. drug use, physical and mental health, psychosocial supports), the mean rating was 5.2 (excellent = 10). Discussion and Conclusions. While participants reported being mainly satisfied with their treatment, results must be viewed within the context of what a consumer reasonably expects to receive from a service. The concept of ‘expectation’ and ‘relative experience’ is crucial in measuring consumer satisfaction among pharmacotherapy consumers.
- 1 July 2008
- Published by Wiley in Drug and Alcohol Review
- Vol. 27 (4) , 393-397
Patients' help‐seeking behaviours for health problems associated with methadone and buprenorphine treatment
Introduction and Aims. Clients in opioid substitution therapy often have considerable unmet health‐care needs. The current study aimed to explore health problems related to opioid substitution therapy among clients on methadone and buprenorphine treatment. Design and Methods. A self‐complete, cross‐sectional survey conducted among 508 patients receiving methadone and buprenorphine treatment at community pharmacies in New South Wales (NSW), Australia. Results. The most common problems for which participants had ever sought help were dental (29.9%), constipation (25.0%) and headache (24.0%). The most common problems for which participants would currently like help were dental (41.1%), sweating (26.4%) and reduced sexual enjoyment (24.2%). There were no significant differences between those currently on methadone and those currently on buprenorphine for any of the health problems explored, nor differences for gender or treatment duration. Participants on methadone doses 100 mg or above were significantly more likely to want help currently for sedation. Discussion and Conclusions. The considerable unmet health care needs among participants in this study suggest that treatment providers should consider improving the detection and response to common health problems related to opioid substitution therapy.
- 1 July 2008
- Published by Wiley in Drug and Alcohol Review
- Vol. 27 (4) , 393-397
Patients' help‐seeking behaviours for health problems associated with methadone and buprenorphine treatment
Introduction and Aims. Clients in opioid substitution therapy often have considerable unmet health‐care needs. The current study aimed to explore health problems related to opioid substitution therapy among clients on methadone and buprenorphine treatment. Design and Methods. A self‐complete, cross‐sectional survey conducted among 508 patients receiving methadone and buprenorphine treatment at community pharmacies in New South Wales (NSW), Australia. Results. The most common problems for which participants had ever sought help were dental (29.9%), constipation (25.0%) and headache (24.0%). The most common problems for which participants would currently like help were dental (41.1%), sweating (26.4%) and reduced sexual enjoyment (24.2%). There were no significant differences between those currently on methadone and those currently on buprenorphine for any of the health problems explored, nor differences for gender or treatment duration. Participants on methadone doses 100 mg or above were significantly more likely to want help currently for sedation. Discussion and Conclusions. The considerable unmet health care needs among participants in this study suggest that treatment providers should consider improving the detection and response to common health problems related to opioid substitution therapy.
- 1 December 2007
- Published by Elsevier in Australian and New Zealand Journal of Public Health
- Vol. 31 (6) , 526-528
Safe storage of methadone takeaway doses – a survey of patient practice
- 1 December 2007
- Published by Elsevier in Australian and New Zealand Journal of Public Health
- Vol. 31 (6) , 526-528
Safe storage of methadone takeaway doses – a survey of patient practice
- 1 July 2007
- Published by Wiley in Drug and Alcohol Review
- Vol. 26 (4) , 411-416
The impact of community pharmacy dispensing fees on the introduction of buprenorphine‐naloxone in Australia
Introduction and Aims. The introduction of buprenorphine‐naloxone in Australia in April 2006 has permitted the revision of takeaway policies in many states and has introduced the possibility of unsupervised treatment. This study explored the implications of the introduction of buprenorphine‐naloxone in terms of cost to patients through a survey of pharmacists' intended pricing practices. The aim of the research was to examine the intentions of pharmacists in relation to fees for buprenorphine‐naloxone and study the potential implications to patients when compared with the existing fee structure for methadone and for buprenorphine alone. Design and Methods. A self‐complete questionnaire was mailed to every community pharmacy in New South Wales (NSW) (n = 593) dispensing methadone or buprenorphine to people with opioid dependence. A response rate of 68.6% (n = 407) was achieved after three mailouts.Results. The majority of pharmacies charged a flat weekly fee for methadone (92.2%; mean = $31.90) and buprenorphine (74.8%; mean = $31.00). The mean intended fees for buprenorphine‐naloxone according to different dosing and takeaway regimens ranged from $19.19 per week for no supervised doses and fortnightly takeaways to a $30.88 per week flat fee. There appeared to be little variation in fee structure irrespective of the takeaway regimen, until reaching the 2 weeks' unsupervised dose regimen. Discussion and Conclusions. This study highlights the importance of the early dissemination of unambiguous information regarding the introduction of a new medication, especially where supervised dispensing through community pharmacies is essential to the provision of treatment. The potential impact upon the successful rollout of a new treatment paradigm that was developed to benefit stable patients in the community may be jeopardised when such processes are not followed. [Winstock AR, Lea T, Ritter A. The impact of community pharmacy dispensing fees on the introduction of buprenorphine‐naloxone in Australia. Drug Alcohol Rev 2007;26:411–416]
- 1 July 2007
- Published by Wiley in Drug and Alcohol Review
- Vol. 26 (4) , 411-416
The impact of community pharmacy dispensing fees on the introduction of buprenorphine‐naloxone in Australia
Introduction and Aims. The introduction of buprenorphine‐naloxone in Australia in April 2006 has permitted the revision of takeaway policies in many states and has introduced the possibility of unsupervised treatment. This study explored the implications of the introduction of buprenorphine‐naloxone in terms of cost to patients through a survey of pharmacists' intended pricing practices. The aim of the research was to examine the intentions of pharmacists in relation to fees for buprenorphine‐naloxone and study the potential implications to patients when compared with the existing fee structure for methadone and for buprenorphine alone. Design and Methods. A self‐complete questionnaire was mailed to every community pharmacy in New South Wales (NSW) (n = 593) dispensing methadone or buprenorphine to people with opioid dependence. A response rate of 68.6% (n = 407) was achieved after three mailouts.Results. The majority of pharmacies charged a flat weekly fee for methadone (92.2%; mean = $31.90) and buprenorphine (74.8%; mean = $31.00). The mean intended fees for buprenorphine‐naloxone according to different dosing and takeaway regimens ranged from $19.19 per week for no supervised doses and fortnightly takeaways to a $30.88 per week flat fee. There appeared to be little variation in fee structure irrespective of the takeaway regimen, until reaching the 2 weeks' unsupervised dose regimen. Discussion and Conclusions. This study highlights the importance of the early dissemination of unambiguous information regarding the introduction of a new medication, especially where supervised dispensing through community pharmacies is essential to the provision of treatment. The potential impact upon the successful rollout of a new treatment paradigm that was developed to benefit stable patients in the community may be jeopardised when such processes are not followed. [Winstock AR, Lea T, Ritter A. The impact of community pharmacy dispensing fees on the introduction of buprenorphine‐naloxone in Australia. Drug Alcohol Rev 2007;26:411–416]